Viromed Medical AG Pushes Forward with New Product Launch and Partnerships

Viromed Medical AG, a leader in cold plasma technology, reports a productive first half of 2025 with significant achievements. The company released its half-year report, highlighting a strategic acquisition and new partnerships. Key among these is the inclusion of healthcare, nutrition, and cosmetics products from pharmedix GmbH.

The collaboration with relyon plasma GmbH boosts production of cold plasma products ViroCAP® and PulmoPlas®. Clinical development showed promising results for PulmoPlas® in treating ventilator-associated pneumonia. Strategic distribution agreements expand Viromed's reach into Asian and European markets.

The company reports a consolidated revenue of EUR 2.4 million and a net loss of EUR 0.8 million, with total equity at EUR 6.6 million. Viromed aims to increase revenues to EUR 8-10 million by year's end, driven by pharmedix GmbH operations.